Clinical Trials Logo

Eye Diseases clinical trials

View clinical trials related to Eye Diseases.

Filter by:
  • Not yet recruiting  
  • « Prev · Page 6

NCT ID: NCT03330054 Not yet recruiting - Type2 Diabetes Clinical Trials

Frequency Of Eye Problems In Type 2 Diabetes With Chronic Kidney Disease

Start date: December 1, 2017
Phase: N/A
Study type: Observational

This study evaluate the frequency and type of eye problem among Type 2 Diabetics with renal impairment and effect of renal impairment and haemodialysis on diabetic retinopathy

NCT ID: NCT03291704 Not yet recruiting - Dry Eye Disease Clinical Trials

Investigating the Effect of At Home Thermal Therapy on Dry Eye Patients With Meibomian Gland Dysfunction

Start date: March 2018
Phase: N/A
Study type: Interventional

The purpose of this pilot study is to determine the feasibility of at home thermal therapy with a wireless, portable device, as an effective management of Meibomian Gland Dysfunction. This will be done by assessing patients for improvement in symptoms and ocular oil gland function after 4 weeks of a daily thermal therapy application.

NCT ID: NCT03098225 Not yet recruiting - Clinical trials for Thyroid Associated Ophthalmopathy

A Trial to Evaluate the Efficacy of Orbital Radiotherapy in Graves' Orbitopathy

ORGO
Start date: January 1, 2024
Phase: Phase 4
Study type: Interventional

Graves' orbitopathy (GO) is a disfiguring and disabling disease that profoundly impairs the quality of life of affected patients. High dose intravenous (iv) glucocorticoids (GC) (ivGC) is a well established, widely used treatment for active GO. The use of systemic glucocorticoids takes advantage from their immune suppressive and antiinflammatory actions, resulting in an overall beneficial effect ranging from ~35 to ~60% of patients in various studies. The intravenous route of administration has been shown to be superior to the oral route, both in terms of GO outcome and side effect profile. The combination of ivGC and orbital radiotherapy (OR) is used routinely in patients with moderate-severe, active GO, as a second-line treatment, as also recommended in the recent Guidelines published by the European Thyroid Association/European Group on Graves' Orbitopathy. Thus, the majority of studies have shown that OR increases the response rate to GC. Those studies were performed using oral GC, whereas it is not known whether OR potentiate also the effects of ivGC. The present study is aimed at determining whether OR potentiate the effects of ivGC in the treatment of moderately severe and active GO, in terms of GO outcome and quality of life. A possible extension of the study can be foreseen, aimed at investigating the very long time GO outcome.

NCT ID: NCT03087006 Not yet recruiting - Depression Clinical Trials

Automatic Self Transcending Meditation (ASTM) in Patients With Dry Eye Disease

Start date: July 1, 2018
Phase: N/A
Study type: Interventional

Patients with dry eye disease (DED) will be randomized to Automatic Self Transcending Meditation (ASTM) plus Treatment as Usual (TAU) or TAU alone to assess changes in Health-related quality of life (HRQoL). HRQoL is a vital construct focusing on impact of health on quality of life. HRQoL data is used in economic evaluations, a component of health economics that compares the cost and consequences of alternative courses of action. This helps policy-makers make complex financial decisions. Along with HRQoL we will measure changes in extent of depression as well as anxiety. Previously published data lacks information of HRQoL in patients with DED. Through this study we shall attempt to correlate HRQoL in this population and assess if ASTM confers changes in HRQoL along with depressive and anxiety symptoms.

NCT ID: NCT02943382 Not yet recruiting - Dry Eye Disease Clinical Trials

Fingerprick Autologous Blood (FAB) in Mebomian Gland Dysfunction (MGD)

Start date: November 2016
Phase: N/A
Study type: Interventional

Dry eye disease remains one of the most common complaints seen in ophthalmic clinics. Causes of dry eye are multifactorial, with the most common cause of evaporative dry eye disease being meibomian gland dysfunction (MGD). Fingerprick autologous blood (FAB) is a novel method which uses a patient's own blood to treat dry eye conditions.

NCT ID: NCT02339142 Not yet recruiting - Clinical trials for Graves Ophthalmopathy

Combined Radiotherapy and Intravenous Steroids for Early Progressive Thyroid Eye Disease

CRISEPTED
Start date: January 2015
Phase: Phase 4
Study type: Interventional

Thyroid eye disease is an autoimmune disorder affecting approximately 50% of individuals with autoimmune thyroid diseases resulting in enlargement of ocular muscles and may lead to congestion of the eyelids and ocular surface, ocular movement restriction and double vision, and optic nerve compression and loss of vision. First line medical therapy is oral or intravenous corticosteroids (CS), which several studies have shown results in reduction of soft tissue congestion, but some studies suggesting that ocular restriction or visual loss may still occur in spite of CS therapy.i External beam radiotherapy (XRT) is second line therapy but is controversial, with some studies suggesting benefit in preventing onset of double vision or optic nerve compression while other studies suggest it has no benefit. Most proponents of XRT for TED believe that it is most effective early in the disease evolution. XRT has been shown to be a safe therapy with few side-effects, although retinopathy changes have developed in a small percentage of diabetics and its use is avoided for diabetics. Combined oral prednisone and XRT has been shown to be more effective in reducing soft tissue inflammation and motility complications than either monotherapy in two different studies. To date there have been no trials comparing combined XRT and iv CS with iv CS alone for early progressive TED to identify potential benefit in reducing the severity of motility disorders or preventing the onset of dysthyroid optic neuropathy. That is the purpose of this study.

NCT ID: NCT00718926 Not yet recruiting - Dry Eye Disease Clinical Trials

The Evaluation of Thiol Redox Status in Conjunctiva of Dry Eye Patients

Start date: August 2008
Phase: N/A
Study type: Observational

Dry eye disease is related with oxidative stress at the ocular surface. GSH is one of the key factor of protect from oxidative stress. To evaluate thiol status of ocular surface cells by monitoring GSH concentration, we can evaluate the severity of dry eye.